Design of the Randomized, Placebo-Controlled Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) Trial.

Koskinas, Konstantinos C; Windecker, Stephan; Buhayer, Aliki; Gencer, Baris; Pedrazzini, Giovanni; Mueller, Christian; Cook, Stephan; Muller, Olivier; Matter, Christian M; Räber, Lorenz; Heg, Dik; Mach, François; investigators, EVOPACS (2018). Design of the Randomized, Placebo-Controlled Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) Trial. Clinical cardiology, 41(12), pp. 1513-1520. Wiley 10.1002/clc.23112

[img] Text
Koskinas ClinCardiol 2018.pdf - Accepted Version
Restricted to registered users only until 13 November 2019.
Available under License Publisher holds Copyright.

Download (742kB) | Request a copy
[img] Text
Koskinas ClinCardiol 2018.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Statins lower low-density lipoprotein cholesterol (LDL-C) and improve clinical outcomes in patients with atherosclerotic cardiovascular disease (CVD). Patients with acute coronary syndromes (ACS) often do not achieve LDL-C targets despite potent statin treatment, and have a particularly high risk of early recurrent events. Evolocumab, a proprotein convertase subtilisin/kexin type (PCSK9)-inhibitor resulting in rapid, marked LDL-C reduction, has been studied in hypercholesterolemic subjects without CVD and stabilized patients with CVD; the feasibility, safety, and efficacy of this treatment initiated in the acute phase of ACS remain unknown. We report the design of Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with ACS (EVOPACS), a phase-3, multicenter, randomized, double-blind, placebo-controlled trial to assess the feasibility, safety, and LDL-C-lowering efficacy of evolocumab on top of atorvastatin 40 mg in patients with ACS. The primary endpoint is percent change in LDL-C from baseline to 8 weeks. Secondary endpoints are adverse events and serious adverse events. Against a background of beneficial cardiovascular effects of statins beyond LDL-C lowering and in view of preclinical evidence of similar effects of PCSK9 inhibition, the study will also address a variety of exploratory endpoints including the change in C-reactive protein and other inflammatory biomarkers; platelet reactivity; and occurrence of contrast-induced acute kidney injury and myocardial injury in patients undergoing cardiac catheterization. An intracoronary imaging sub-study will assess the change from baseline in the lipid core burden index in non-culprit lesions, as assessed by serial near-infrared spectroscopy. Recruitment began in January 2018 and enrolment of 308 patients is planned. This article is protected by copyright. All rights reserved.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Koskinas, Konstantinos; Windecker, Stephan; Räber, Lorenz and Heg, Dierik Hans

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0160-9289

Publisher:

Wiley

Language:

English

Submitter:

Tanya Karrer

Date Deposited:

16 Nov 2018 00:25

Last Modified:

14 Feb 2019 11:45

Publisher DOI:

10.1002/clc.23112

PubMed ID:

30421481

Uncontrolled Keywords:

Acute coronary syndrome Lipidology PCSK9 inhibitor

BORIS DOI:

10.7892/boris.121273

URI:

https://boris.unibe.ch/id/eprint/121273

Actions (login required)

Edit item Edit item
Provide Feedback